Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The
effects and safety of caspofungin and corticosteroids is not certain in this population. All
Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin
and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28
day mortality, the second outcome are time of respiratory rate decreases to less than 25
breath per minute, body temperature lower than 37.3℃.